Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
"What's in a name? That which we call a rose/By any other name would smell as sweet." (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and pediatric endocrine societies now proposes changing the name of "diabetes insipidus" to "Arginine Vasopressin Deficiency (AVP-D)" for central etiologies, and "Arginine Vasopressin Resistance (AVP-R)" for nephrogenic etiologies. This editorial provides both the historical context and the rational for this proposed name change.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1507/endocrj.EJ20220831 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lithium-induced kidney injury and fibrosis: A versatile model to explore cellular pathways of injury and repair.
Physiol Rep
September 2025
Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Lithium-induced kidney injury is commonly associated with the development of nephrogenic diabetes insipidus. Longer term lithium exposure is associated with the development of chronic interstitial fibrosis. The mechanisms of lithium-induced kidney injury are multifaceted, affecting many intracellular cell signaling pathways associated with cell cycle regulation, cell proliferation, and subsequent increased extracellular matrix formation and interstitial fibrosis.
View Article and Find Full Text PDFWater deprivation test in children: challenging but still necessary for the differential diagnosis of polyuria-polydipsia syndrome.
Am J Physiol Regul Integr Comp Physiol
September 2025
Department of Pediatrics, Ribeirao Preto Medical School - University of Sao Paulo, Brazil.
The differential diagnosis within polyuria-polydipsia syndrome, especially in the pediatric population, remains challenging. Despite its limited accuracy, the water deprivation test (WDT) is the reference test in pediatrics. We retrospectively analyzed performed in 65 pediatric patients (mean age 8.
View Article and Find Full Text PDFCopeptin in the diagnosis and management of renal tubular disorders.
Pediatr Nephrol
September 2025
Pediatric Nephrology Department, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain.
Copeptin, a stable glycopeptide derived from the precursor of arginine vasopressin (AVP), has emerged as a valuable surrogate biomarker for AVP due to its stability and ease of measurement. This narrative review explores the physiological role of copeptin, its utility as a diagnostic and prognostic biomarker in different kidney diseases, and its clinical relevance in renal tubular disorders. The clinical application of copeptin as a diagnostic biomarker is best established in the differential diagnosis of polyuria-polydipsia syndrome (PPS), distinguishing nephrogenic diabetes insipidus (NDI) from central diabetes insipidus (CDI) and primary polydipsia (PP).
View Article and Find Full Text PDFNephrogenic Diabetes Insipidus: Three Decades of Clinical Reality.
Cureus
August 2025
Pediatric Nephrology, Hospital Pediátrico, Unidade Local de Saúde de Coimbra, Coimbra, PRT.
Introduction Nephrogenic diabetes insipidus (NDI) is a rare condition caused by renal resistance to the action of antidiuretic hormone (ADH) at the level of the distal tubule, resulting in impaired urinary concentration and consequent polyuria. NDI may be hereditary, most commonly X-linked due to AVPR2 gene mutations, or acquired. Objective To characterize the clinical features, management strategies, and outcomes of patients with NDI followed at a tertiary pediatric nephrology center.
View Article and Find Full Text PDFLong-term impact of growth hormone therapy on mortality and type 2 diabetes in Prader-Willi syndrome: a nationwide cohort study.
Front Endocrinol (Lausanne)
September 2025
Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Background: Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by severe multisystem comorbidities and increased mortality. Although growth hormone therapy (GHT) is widely used as standard care, population-based evidence on its long-term safety, particularly in relation to mortality and type 2 diabetes mellitus (T2DM), remains limited. We aimed to investigate the associations between GHT duration, mortality, and T2DM incidence in PWS.
View Article and Find Full Text PDF